GlaxoSmithKline
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
Effectiveness of Belimumab Treatment in a Subpopulation of Systemic Lupus Erythematosus (SLE) Patients: a Pooled Analysis of BLISS-52 and BLISS-76
Completed
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- First Posted Date
- 2013-08-02
- Last Posted Date
- 2013-09-16
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1016
- Registration Number
- NCT01914770
Characterisation of T-cell Response to Keyhole Limpet Hemocyanin (KLH) and Tuberculin Purified Protein Derivative (PPD)
Phase 1
Completed
- Conditions
- Dermatitis
- Interventions
- Other: PBS (0.1 mL)Other: KLH 0.1 mgOther: Tuberculin PPDOther: KLH 5 mg
- First Posted Date
- 2013-07-29
- Last Posted Date
- 2017-05-15
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 24
- Registration Number
- NCT01910662
- Locations
- 🇬🇧
GSK Investigational Site, Cambridge, United Kingdom
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccines
Phase 1
Completed
- Conditions
- Infections, Respiratory Syncytial Virus
- Interventions
- Biological: RSV vaccine GSK3003892A (formulation 1)Biological: RSV vaccine GSK3003893A (formulation 2)Biological: RSV vaccine GSK3003895A (formulation 3)Biological: RSV vaccine GSK3003896A (formulation 4)Biological: RSV vaccine GSK3003898A (formulation 5)Biological: RSV vaccine GSK3003899A (formulation 6)Drug: Placebo comparator
- First Posted Date
- 2013-07-23
- Last Posted Date
- 2017-05-30
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 128
- Registration Number
- NCT01905215
- Locations
- 🇨🇦
GSK Investigational Site, Toronto, Ontario, Canada
Post-marketing Safety Study to Assess the Risk of Spontaneous Abortions in Women Exposed to Cervarix Residing in UK
Completed
- Conditions
- Infections, Papillomavirus
- Interventions
- Other: Data CollectionBiological: Cervarix
- First Posted Date
- 2013-07-23
- Last Posted Date
- 2013-09-30
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1046
- Registration Number
- NCT01905462
- Locations
- 🇬🇧
GSK Investigational Site, London, United Kingdom
GSK2339345 Hypertussive Challenge Study
- First Posted Date
- 2013-07-15
- Last Posted Date
- 2017-04-05
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 16
- Registration Number
- NCT01899768
- Locations
- 🇬🇧
GSK Investigational Site, Belfast, United Kingdom
Pharmacokinetics Of Umeclidinium and Vilanterol in Healthy Chinese, a Randomized, Open Label, 3 Crossover Study.
Phase 1
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Drug: UMEC/VI 62.5/25 mcgDrug: UMEC/VI 125/25 mcgDrug: UMEC 125 mcgDrug: UMEC 62.5 mcgDrug: VI 25 mcg
- First Posted Date
- 2013-07-15
- Last Posted Date
- 2017-06-07
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 20
- Registration Number
- NCT01899638
- Locations
- 🇨🇳
GSK Investigational Site, Shanghai, China
The Purpose of the This Study is to Evaluate the Spirometric Effect (Trough FEV1) of Umeclidinium/Vilanterol 62.5/25 mcg Once Daily Compared With Tiotropium 18mcg Once Daily Over a a 12-week Treatment Period in Subjects With COPD Who Continue to Have Symptoms on Tiotropium
Phase 3
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Drug: Umeclidinium/Vilanterol 62.5/25 mcg
- First Posted Date
- 2013-07-15
- Last Posted Date
- 2018-01-24
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 497
- Registration Number
- NCT01899742
- Locations
- 🇺🇦
GSK Investigational Site, Vinnytsya, Ukraine
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Repeat Doses of GSK2330672 Administration in Subjects With Primary Biliary Cirrhosis (PBC) and Symptoms of Pruritus
Phase 2
Completed
- Conditions
- Cholestasis, Intrahepatic
- Interventions
- First Posted Date
- 2013-07-15
- Last Posted Date
- 2017-08-01
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 22
- Registration Number
- NCT01899703
- Locations
- 🇬🇧
GSK Investigational Site, Newcastle upon Tyne, United Kingdom
A Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability, Immunogenicity, and Pharmacodynamics (PD) of GSK2800528 in Healthy Subjects.
Phase 1
Completed
- Conditions
- Psoriasis
- Interventions
- Drug: GSK2800528, solution for injectionDrug: Placebo (0.9% w/v Sodium Chloride), solution for injectionDrug: Adalimumab, solution for injection
- First Posted Date
- 2013-07-15
- Last Posted Date
- 2017-05-11
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 45
- Registration Number
- NCT01899755
- Locations
- 🇬🇧
GSK Investigational Site, London, United Kingdom
Pharmacokinetic Study in Healthy Volunteers to Characterise the Exposure of Fluticasone Furoate (FF), Vilanterol (VI) and Umeclidinium (UMEC) at Two Different Doses
Phase 1
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Drug: FF 400 mcgDrug: UMEC 500 mcgDrug: UMEC 250 mcgDrug: VI 100 mcg
- First Posted Date
- 2013-07-10
- Last Posted Date
- 2017-05-15
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 48
- Registration Number
- NCT01894386
- Locations
- 🇺🇸
GSK Investigational Site, Baltimore, Maryland, United States